AIM ImmunoTech
AIM
AIM ImmunoTech (AIM) news
Recent news
AIM ImmunoTech Q2 EPS -$0.43
AInvest Wire · Aug 10, 2026AIM ImmunoTech - enters proposal agreement with Sterling Pharma Solutions on July 31, 2026 - SEC filing
AInvest Wire · Aug 6, 2026Aim ImmunoTech - Duripanc overall survival endpoint analysis expected to begin June 2027
AInvest Wire · Aug 3, 2026AIM ImmunoTech announces release of new CEO Corner segment highlighting growing momentum across pancreatic cancer program
AInvest Wire · Jul 7, 2026AIM ImmunoTech - Duripanc secondary endpoint analysis expected to begin June 2027
AInvest Wire · Jun 18, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.